Medical Condition News

RSS

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

Genentech, a member of the Roche Group, today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint.

15 Jul 2011

Simple dental algorithm can effectively identify patients with unrecognized diabetes

In a study, Identification of unrecognized diabetes and pre-diabetes in a dental setting, published in the July 2011 issue of the Journal of Dental Research, researchers at Columbia University College of Dental Medicine found that dental visits represented a chance to intervene in the diabetes epidemic by identifying individuals with diabetes or pre-diabetes who are unaware of their condition.

15 Jul 2011

Study: Early-stage melanomas can help predict tumor metastasis

Wanderlust in a person can be admirable or romantic. In a cancerous tumor, it may be lethal. Most deaths from cancer result from tumor cells that have strayed from their original location to insinuate their way into distant tissues. With few exceptions, however, doctors have little way of determining whether a newly formed tumor is more likely to remain idle or send invader cells to other parts of the body.

15 Jul 2011

Tocotrienol could help reduce stroke damage

Preventive supplementation with a natural form of vitamin E called tocotrienol could help reduce brain damage caused by strokes, researchers reported today at the 2nd International Conference on Tocotrienols and Chronic Diseases.

15 Jul 2011

UTHealth enrolls first patient in new stem cell therapy trial for ischemic stroke

The first Texas patient has been enrolled by researchers at The University of Texas Health Science Center at Houston in the country's first double-blind clinical trial studying the safety and efficacy of an innovative stem cell therapy that can be given up to 19 days after an ischemic stroke.

15 Jul 2011

Babies have far less ability to recognize rapidly changing images than adults

Babies have far less ability to recognize rapidly changing images than adults, according to research from the UC Davis Center for Mind and Brain. The results show that while infants can perceive flicker or movement, they may not be able to identify the individual elements within a moving or changing scene as well as an adult.

15 Jul 2011

Young investigators to receive Brain & Behavior Research Foundation awards

Brain & Behavior Research Foundation will honor five outstanding researchers at the Annual Klerman and Freedman Awards event in New York City.

15 Jul 2011

Bariatric surgery cost-effective for all obese

Bariatric surgery is not only cost-effective for treating people who are severely obese, but also for those who are mildly obese, according to a new study from Washington University School of Medicine in St. Louis.

15 Jul 2011

CVS Caremark adds Access' MuGard to pharmacy benefit network

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that its lead product for oral mucositis, MuGard, has been added to CVS Caremark's pharmacy benefit network.

15 Jul 2011

Short telomeres may increase risk of emphysema

Telomeres, the body's own cellular clocks, may be a crucial factor underlying the development of emphysema, according to research from Johns Hopkins University.

15 Jul 2011

ASTRO develops white paper on safe use of intensity modulated radiation therapy

As part of the Target Safely initiative, the American Society for Radiation Oncology (ASTRO) has developed a white paper, the first of a series of such papers, on the safe use of integrating intensity modulated radiation therapy (IMRT) into the radiation oncology clinic.

15 Jul 2011

Camel blood can help scientists fight against cancer

Nanobodies produced from camel blood have unique properties, which can be used in future drug development. New research published in Journal of Controlled Release confirms that camel blood can help scientists in the fight against cancer.

15 Jul 2011

BioMarin commences BMN 673 Phase 1 trial in hematological malignancies

BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.

15 Jul 2011

Cancer may soon affect 40% of UK’s population: Report

Macmillan Cancer Support this Thursday revealed warning estimates that four in 10 people in the UK will get cancer at some point in their lives, up from one in three a decade ago. Cancer experts now believe 42% of Britons will get the disease.

14 Jul 2011

Michael J. Fox Foundation awards Impax $400,000 grant for research of IPX066 for Parkinson’s disease

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., has been awarded funding of up to $400,000 by The Michael J. Fox Foundation for ongoing clinical research of the Company's investigational carbidopa-levodopa extended release (CD-LD ER) product IPX066, which is intended to treat the motor symptoms of Parkinson's disease (PD).

14 Jul 2011

Eli Lilly makes charitable contribution to Patient Advocate Foundation

Eli Lilly and Company announced that it has made a charitable contribution to the Patient Advocate Foundation.

14 Jul 2011

Safety guidelines for preventing injuries from gasoline

Summer is in full swing and injuries from gasoline and other accelerants are on the rise. The University of Michigan Health System's Trauma Burn Center saw 14 such burns in the past month.

14 Jul 2011

Two promising projects focus on new treatments for cystic fibrosis

Two promising projects have been selected to undergo preclinical testing as part of the Cystic Fibrosis Technology Initiative.

14 Jul 2011

Study examines psychological problems among adopted children

Over 4,000 international adoptions take place in Spain every year. Although the process of adaptation of these children is very similar to that of those living with their biological parents, some studies show that they are more prone to being hyperactive, to having behavioural problems, a low self-esteem and doing poorly in school.

14 Jul 2011

USPTO awards patent for Convergen LifeSciences' CNVN202 to treat lung cancer

Convergen LifeSciences, Inc. announced today that another United States Patent 7,977,468 has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services.

14 Jul 2011